देश: दक्षिण अफ़्रीका
भाषा: अंग्रेज़ी
स्रोत: South African Health Products Regulatory Authority (SAHPRA)
Ranbaxy
INDICATIONS [/za_1254.html#1] [/za_1254.html#1] [/za_1254.html#1] CONTRA-INDICATIONS [/za_1254.html#1] [/za_1254.html#1] DOSAGE [/za_1254.html#1] [/za_1254.html#1] SIDE-EFFECTS [/za_1254.html#1] [/za_1254.html#1] [/za_1254.html#1] PREGNANCY [/za_1254.html#1] [/za_1254.html#1] OVERDOSE [/za_1254.html#1] IDENTIFICATION [/za_1254.html#1] [/za_1254.html#1] PATIENT INFORMATION HISTAK 75 TABLETS SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): HISTAK 75 TABLETS COMPOSITION: Each film coated tablet contains Ranitidine hydrochloride equivalent to RANITIDINE 75 mg PHARMACOLOGICAL CLASSIFICATION: A11.4.3 Antacids-other PHARMACOLOGICAL ACTION: RANITIDINE inhibits the basal and noctural gastric acid by competitive inhibition of the interaction of histamine at the histamine H 2 -receptors of the parietal cells. Ranitidine reduces both the volume of gastric juices and its H + concentration. RANITIDINE is rapidly and well absorbed from the gastro-intestinal tract with peak concentrations in plasma occuring within 1 or 2 hours after oral administration. The bioavailability of ranitidine is about 50%. The absorption is not significantly impaired by the coadministration of food or antacids. About 15% of ranitidine is bound to plasma proteins. The elimination half-life is about 2 to 3 hours. Ranitidine is excreted via the kidneys in the free and metabolised forms. Its major metabolite is the N-oxide, S-oxide and desmethyl ranitidine. Ranitidine generally does not bind to microsomal cytochrome P 450 . INDICATIONS: RANITIDINE 75 tablets are indicated for the prevention and symptomatic relief of heartburn and hyperacidity. CONTRA-INDICATIONS: Ranitidine is contraindicated in patients hypersensitive to ranitidine or any of the histamine H 2 -receptor antagonists. The पूरा दस्तावेज़ पढ़ें